| Literature DB >> 8837609 |
A A Vandenbark1, Y K Chou, R Whitham, M Mass, A Buenafe, D Liefeld, D Kavanagh, S Cooper, G A Hashim, H Offner.
Abstract
A T-cell receptor (TCR) peptide vaccine from the V beta 5.2 sequence expressed in multiple sclerosis (MS) plaques and on myelin basic protein (MBP)-specific T cells boosted peptide-reactive T cells in patients with progressive MS. Vaccine responders had a reduced MBP response and remained clinically stable without side effects during one year of therapy, whereas nonresponders had an increased MBP response and progressed clinically. Peptide-specific T helper 2 cells directly inhibited MBP-specific T helper 1 cells in vitro through the release of interleukin-10, implicating a bystander suppression mechanism that holds promise for treatment of MS and other autoimmune diseases.Entities:
Mesh：
Substances：
Year: 1996 PMID： 8837609 DOI： 10.1038/nm1096-1109
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440